Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Psyence Biomedical ( (PBM) ) has provided an update.
On February 12, 2026, Psyence Biomedical Ltd. held its adjourned annual and special meeting of shareholders after a prior lack of quorum, with about 29.3% of eligible common shares represented, satisfying quorum requirements. Shareholders elected all director nominees and confirmed MNP LLP as auditor for the coming year, authorizing the board to set auditor compensation.
Investors also approved a special resolution granting the board authority to carry out one or more consolidations of the company’s common shares at a ratio of up to 250-for-1, at a time and final ratio of the board’s choosing. The vote strengthens the company’s governance and capital-structure flexibility, positioning Psyence Biomedical to better address listing requirements and manage its share base amid the evolving psychedelics-focused biopharmaceutical market.
More about Psyence Biomedical
Psyence Biomedical Ltd., listed on Nasdaq as PBM, is a multi-asset, vertically integrated biopharmaceutical company focused on psychedelic-based therapeutics. It develops nature-derived, non-synthetic psilocybin and ibogaine medicines aimed at addressing unmet mental health needs through evidence-based, regulator-approved treatments.
Average Trading Volume: 355,047
Technical Sentiment Signal: Sell
Current Market Cap: $2.85M
For detailed information about PBM stock, go to TipRanks’ Stock Analysis page.